Giovanni Gerardo Cardellino

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

Zev A. Wainberg, Peter C. Enzinger, Yoon‐Koo Kang et al. · The Lancet Oncology · 2022 · 201 citations

Surgical Oncology, Esophageal Cancer, Gastrointestinal Oncology +11

Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications

Fabio Puglisi, Alessandro Follador, Alessandro Marco Minisini et al. · Annals of Oncology · 2005 · 158 citations · Full text

Baseline Staging Tests, Breast Oncology, Cancer Detection +10

Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for <i>RAS</i> and <i>BRAF</i> Wild-type Metastatic Colorectal Cancer

Chiara Cremolini, Carlotta Antoniotti, Sara Lonardi et al. · JAMA Oncology · 2018 · 111 citations · Full text

INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

Filippo Pietrantonio, Alessandra Raimondi, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 90 citations

Surgical Oncology, Cancer Management, Immunology +22

The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients

Debora Basile, A. Parnofiello, Maria Grazia Vitale et al. · Journal of Cachexia Sarcopenia and Muscle · 2019 · 76 citations · Full text